Table 1.
“Diagnostic ratios”: definitions, examples and explanation.
Figure 1.
Time series of “total generic market share” in 19 LMICs and the U.S.
LEGEND: The trend (change in total generic market share/yr) was calculated using a simple linear regression model. Trend: United States 1.54%/yr; LAC 1.12%/yr; Middle East plus South Africa (MeSA) 0.38%/yr; Asia 0.31%/yr. A t test for regressions were all significant [p<0.05].
Figure 2.
Time series “branded generic” market share in 19 LMICs and the U.S.
LEGEND: The trend (change in branded generic market share/yr) was calculated using a simple linear regression model.Trend: United States −1.15%/yr; LAC −0.34%/yr; Middle East plus South Africa (MeSA) 0.47%/yr; Asia 0.61%/yr. A t test for regressions were all significant [p<0.05]. The number of countries in Figure 2 are the same as in Figure 1.
Figure 3.
Time series of “unbranded generic” market share in 19 LMICs and the U.S.
LEGEND: The trend (change in branded generic market share/yr) was calculated using a simple linear regression model.Trend: United States 2.90%/yr; LAC 1.46%/yr; Middle East plus South Africa (MeSA) −0.08%/yr; Asia −0.27%/yr. A t test for regressions were all significant [p<0.05]. The number of countries in Figure 3 are the same as in Figure 1.
Table 2.
Market share of unbranded, “other” (branded generic), and originator products in 2001 and 2011 by country.
Figure 4.
The distribution of diagnostic ratios (in the 4 categories) for each countries' 30 originator pharmaceutical substances.
The number in each bar is the number of medicines falling into the respective category.
Table 3.
Pharmaceutical substances with decreasing originator market share (2001–2011) and no generic counterpart on market.